Physician profile
Michael Phillips
NPI 1972941243
$3,179.94
in general payments reported to CMS, 2019-2025
20 companies · $669 in 2025
The $669 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.24 · 2020: $37.15 · 2021: $421 · 2022: $482 · 2023: $416 · 2024: $1,100 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524.78 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $453.66 | 2021-2025 | Xifaxan |
| Celgene Corporation | $350.29 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $281.52 | 2021-2025 | Entyvio |
| Boston Scientific Corporation | $221.71 | 2024-2025 | Axios |
| Pfizer INC. | $195.39 | 2022-2025 | |
| Ardelyx, INC. | $185.69 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $183.30 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $179.55 | 2024-2025 | Rezdiffra |
| Intera Oncology, INC | $166.92 | 2024 | Intera |
| Medtronic, INC. | $166.37 | 2024 | Beacon |
| Conmed Corporation | $96.49 | 2024 | Conmed Biliary, Conmed Generators, Conmed Hemostasis |
| Alnylam Pharmaceuticals INC. | $37.71 | 2022-2023 | Givlaari |
| Lilly USA, LLC | $34.87 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $18.78 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.29 | 2022 | |
| Amgen INC. | $17.04 | 2025 | Uplizna |
| Daiichi Sankyo INC. | $16.57 | 2022 | |
| Gilead Sciences, INC. | $16.07 | 2021 | |
| Shire North American Group INC | $15.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.